{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126346","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.108073+00:00","generated_at":"2026-05-30T00:57:26.153551+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"4DMT reports Q3 2024 net loss $43.8M, cash $551M; 4D-150 Phase 3 on track for Q1 2025","bullets":["Net loss $43.8M (vs $10.3M Q3 2023); R&D expense $38.5M (vs $25.1M) on trial progression.","Cash & equivalents $551M; expected to fund operations at least into H1 2027.","Positive 4D-150 interim data: 83% injection reduction in severe population; 70-87% 52-week injection-free rate.","4FRONT-1 Phase 3 trial for 4D-150 in wet AMD initiation expected Q1 2025.","New senior hires: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophthalmology)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126346","json":"https://secwatch.observer/filing/0000950170-24-126346.json","markdown":"https://secwatch.observer/filing/0000950170-24-126346.md","text":"https://secwatch.observer/filing/0000950170-24-126346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/0000950170-24-126346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:57:26.153551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}